Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy

[1] Wullschleger, S., Loewith, R. and Hall, M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471–484. http://dx.doi.org/10.1016/j.cell.2006.01.01610.1016/j.cell.2006.01.016Search in Google Scholar PubMed

[2] Zoncu, R., Efeyan, A. and Sabatini, D.M. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12 (2011) 21–35. http://dx.doi.org/10.1038/nrm302510.1038/nrm3025Search in Google Scholar PubMed PubMed Central

[3] Laplante, M. and Sabatini, D.M. mTOR signaling in growth control and disease. Cell 149 (2012) 274–293. http://dx.doi.org/10.1016/j.cell.2012.03.01710.1016/j.cell.2012.03.017Search in Google Scholar PubMed PubMed Central

[4] Cornu, M., Albert, V. and Hall, M.N. mTOR in aging, metabolism, and cancer. Curr. Opin. Genet. Dev. 23 (2013) 53–62. http://dx.doi.org/10.1016/j.gde.2012.12.00510.1016/j.gde.2012.12.005Search in Google Scholar PubMed

[5] Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y. and Mills, G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005) 988–1004. http://dx.doi.org/10.1038/nrd190210.1038/nrd1902Search in Google Scholar PubMed

[6] Sarbassov, D.D., Guertin, D.A., Ali, S.M. and Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098–1101. http://dx.doi.org/10.1126/science.110614810.1126/science.1106148Search in Google Scholar PubMed

[7] Hung, C.M., Garcia-Haro, L., Sparks, C.A. and Guertin, D.A. mTORdependent cell survival mechanisms. Cold Spring Harb, Perspect. Biol. 4 (2012) DOI: 10.1101/cshperspect.a008771. 10.1101/cshperspect.a008771Search in Google Scholar PubMed PubMed Central

[8] Shaw, R.J. and Cantley, L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424–430. http://dx.doi.org/10.1038/nature0486910.1038/nature04869Search in Google Scholar PubMed

[9] Liu, W., Zhou, Y., Reske, S.N. and Shen, C. PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res. 28 (2008) 3613–3620. Search in Google Scholar

[10] McCubrey, J.A., Steelman, L.S., Chappell, W.H., Abrams, S.L., Franklin, R.A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., Mazzarino, M.C., Fagone, P., Nicoletti, F., Bäsecke, J., Mijatovic, S., Maksimovic-Ivanic, D., Milella, M., Tafuri, A., Chiarini, F., Evangelisti, C., Cocco, L. and Martelli, A.M. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 3 (2012) 1068–1111. Search in Google Scholar

[11] Rodon, J., Dienstmann, R., Serra, V. and Tabernero, J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10 (2013) 143–153. http://dx.doi.org/10.1038/nrclinonc.2013.1010.1038/nrclinonc.2013.10Search in Google Scholar PubMed

[12] Bjornsti, M.A. and Houghton, P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4 (2004) 335–348. http://dx.doi.org/10.1038/nrc136210.1038/nrc1362Search in Google Scholar PubMed

[13] Hanahan, D. and Weinberg, R.A. The hallmarks of cancer. Cell 100 (2000) 57–70. http://dx.doi.org/10.1016/S0092-8674(00)81683-910.1016/S0092-8674(00)81683-9Search in Google Scholar

[14] Luo, J., Solimini, N.L. and Elledge, S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136 (2009) 823–837. http://dx.doi.org/10.1016/j.cell.2009.02.02410.1016/j.cell.2009.02.024Search in Google Scholar

[15] Dick, F.A. and Rubin, S.M. Molecular mechanisms underlying RB protein function. Nat. Rev. Mol. Cell Biol. 14 (2013) 297–306. http://dx.doi.org/10.1038/nrm356710.1038/nrm3567Search in Google Scholar

[16] Chen, H.Z., Tsai, S.Y. and Leone, G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 9 (2009) 785–797. http://dx.doi.org/10.1038/nrc269610.1038/nrc2696Search in Google Scholar

[17] Manning, B.D. and Cantley, L.C. AKT/PKB signaling: navigating downstream. Cell 129 (2007) 1261–1274. http://dx.doi.org/10.1016/j.cell.2007.06.00910.1016/j.cell.2007.06.009Search in Google Scholar

[18] Heitman, J., Movva, N.R. and Hall, M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253 (1991) 905–909. http://dx.doi.org/10.1126/science.171509410.1126/science.1715094Search in Google Scholar

[19] Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J.L., Bonenfant, D., Oppliger, W., Jenoe, P. and Hall, M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10 (2002) 457–468. http://dx.doi.org/10.1016/S1097-2765(02)00636-610.1016/S1097-2765(02)00636-6Search in Google Scholar

[20] Sarbassov, D.D., Ali, S.M. and Sabatini, D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17 (2005) 596–603. http://dx.doi.org/10.1016/j.ceb.2005.09.00910.1016/j.ceb.2005.09.009Search in Google Scholar PubMed

[21] Soulard, A. and Hall, M.N. SnapShot: mTOR signaling. Cell 129 (2007) 434. http://dx.doi.org/10.1016/j.cell.2007.04.01010.1016/j.cell.2007.04.010Search in Google Scholar PubMed

[22] Polak, P. and Hall, M.N. mTOR and the control of whole body metabolism. Curr. Opin. Cell Biol. 21 (2009) 209–218. http://dx.doi.org/10.1016/j.ceb.2009.01.02410.1016/j.ceb.2009.01.024Search in Google Scholar PubMed

[23] Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., Wang, C.Y., He, X., MacDougald, O.A., You, M., Williams, B.O. and Guan, K.L. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126 (2006) 955–968. http://dx.doi.org/10.1016/j.cell.2006.06.05510.1016/j.cell.2006.06.055Search in Google Scholar PubMed

[24] Li, Y., Inoki, K., Vacratsis, P. and Guan, K.L. The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J. Biol. Chem. 278 (2003) 13663–13671. http://dx.doi.org/10.1074/jbc.M30086220010.1074/jbc.M300862200Search in Google Scholar PubMed

[25] Lee, D.F., Kuo, H.P., Chen, C.T., Hsu, J.M., Chou, C.K., Wei, Y., Sun, H.L., Li, L.Y., Ping, B., Huang, W.C., He, X., Hung, J.Y., Lai, C.C., Ding, Q., Su, J.L., Yang, J.Y., Sahin, A.A., Hortobagyi, G.N., Tsai, F.J., Tsai, C.H. and Hung, M.C. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130 (2007) 440–455. http://dx.doi.org/10.1016/j.cell.2007.05.05810.1016/j.cell.2007.05.058Search in Google Scholar PubMed

[26] Astrinidis, A., Senapedis, W., Coleman, T.R. and Henske, E.P. Cell cycleregulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J. Biol. Chem. 278 (2003) 51372–51379. http://dx.doi.org/10.1074/jbc.M30395620010.1074/jbc.M303956200Search in Google Scholar PubMed

[27] Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T.P. and Guan, K.L. Regulation of TORC1 by Rag GTPases in nutrient response. Nat. Cell Biol. 10 (2008) 935–945. http://dx.doi.org/10.1038/ncb175310.1038/ncb1753Search in Google Scholar PubMed PubMed Central

[28] Meric-Bernstam, F. and Gonzalez-Angulo, A.M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 27 (2009) 2278–2287. http://dx.doi.org/10.1200/JCO.2008.20.076610.1200/JCO.2008.20.0766Search in Google Scholar PubMed PubMed Central

[29] Yap, T.A., Garrett, M.D., Walton, M.I., Raynaud, F., de Bono, J.S. and Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8 (2008) 393–412. http://dx.doi.org/10.1016/j.coph.2008.08.00410.1016/j.coph.2008.08.004Search in Google Scholar PubMed

[30] Moldovan, G.L. and D’Andrea, A.D. How the fanconi anemia pathway guards the genome. Annu. Rev. Genet. 43 (2009) 223–249. http://dx.doi.org/10.1146/annurev-genet-102108-13422210.1146/annurev-genet-102108-134222Search in Google Scholar PubMed PubMed Central

[31] Kitao, H. and Takata, M. Fanconi anemia: a disorder defective in the DNA damage response. Int. J. Hematol. 93 (2011) 417–424. http://dx.doi.org/10.1007/s12185-011-0777-z10.1007/s12185-011-0777-zSearch in Google Scholar PubMed

[32] Kim, H. and D’Andrea, A.D. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 26 (2012) 1393–1408. http://dx.doi.org/10.1101/gad.195248.11210.1101/gad.195248.112Search in Google Scholar PubMed PubMed Central

[33] Kee, Y. and D’Andrea, A.D. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 24 (2010) 1680–1694. http://dx.doi.org/10.1101/gad.195531010.1101/gad.1955310Search in Google Scholar

[34] Knipscheer, P., Raschle, M., Smogorzewska. A., Enoiu, M., Ho, T.V., Scharer, O.D., Elledge, S.J. and Walter, J.C. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 326 (2009) 1698–1701. http://dx.doi.org/10.1126/science.118237210.1126/science.1182372Search in Google Scholar

[35] Joo, W., Xu, G., Persky, N.S., Smogorzewska, A., Rudge, D.G., Buzovetsky, O., Elledge, S.J. and Pavletich, N.P. Structure of the FANCIFANCD2 complex: insights into the Fanconi anemia DNA repair pathway. Science 333 (2011) 312–316. http://dx.doi.org/10.1126/science.120580510.1126/science.1205805Search in Google Scholar

[36] Shen, C., Oswald, D., Phelps, D., Cam, H., Pelloski, C.E., Pang, Q. and Houghton, P.J. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double strand breaks. Cancer Res. 73 (2013) 3393–3401. http://dx.doi.org/10.1158/0008-5472.CAN-12-428210.1158/0008-5472.CAN-12-4282Search in Google Scholar

[37] Kastan, M.B. and Bartek, J. Cell-cycle checkpoints and cancer. Nature 432 (2004) 316–323. http://dx.doi.org/10.1038/nature0309710.1038/nature03097Search in Google Scholar

[38] Guo, F., Li, J., Du, W., Zhang, S., O’Connor, M., Thomas, G., Kozma, S., Zingarelli, B., Pang, Q. and Zheng, Y. mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells. Leukemia 27 (2013) 2040–2046. http://dx.doi.org/10.1038/leu.2013.9310.1038/leu.2013.93Search in Google Scholar

[39] Guo, F., Li, J., Zhang, S., Du, W., Amarachintha, S., Sipple, J., Phelan, J., Grimes, H.L., Zheng, Y. and Pang, Q. mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression. Leukemia 28 (2014) 203–206. http://dx.doi.org/10.1038/leu.2013.21510.1038/leu.2013.215Search in Google Scholar

[40] Huang, M., Zhou, Z. and Elledge, S.J. The DNA replication and damage checkpoint pathways induce transcription by inhibition of the Crt1 repressor. Cell 94 (1998) 595–605. http://dx.doi.org/10.1016/S0092-8674(00)81601-310.1016/S0092-8674(00)81601-3Search in Google Scholar

[41] Zhao, X. and Rothstein, R. The Dun1 checkpoint kinase phosphorylates and regulates the ribonucleotide reductase inhibitor Sml1. Proc. Natl. Acad. Sci. USA 99 (2002) 3746–3751. http://dx.doi.org/10.1073/pnas.06250229910.1073/pnas.062502299Search in Google Scholar PubMed PubMed Central

[42] Kolberg, M., Strand, K.R., Graff, P. and Andersson, K.K. Structure, function, and mechanism of ribonucleotide reductases. Biochim. Biophys. Acta 1699 (2004) 1–34. http://dx.doi.org/10.1016/j.bbapap.2004.02.00710.1016/j.bbapap.2004.02.007Search in Google Scholar PubMed

[43] Shen, C., Lancaster, C.S., Shi, B., Guo, H., Thimmaiah, P. and Bjornsti, M.A. TOR signaling is a determinant of cell survival in response to DNA damage. Mol. Cell. Biol. 27 (2007) 7007–7017. http://dx.doi.org/10.1128/MCB.00290-0710.1128/MCB.00290-07Search in Google Scholar PubMed PubMed Central

[44] Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y. and Nakamura, Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404 (2000) 42–49. http://dx.doi.org/10.1038/3500350610.1038/35003506Search in Google Scholar PubMed

[45] D’Angiolella, V., Donato, V., Forrester, F.M., Jeong. Y.T., Pellacani, C., Kudo, Y., Saraf, A., Florens, L., Washburn, M.P. and Pagano, M. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 149 (2012) 1023–1034. http://dx.doi.org/10.1016/j.cell.2012.03.04310.1016/j.cell.2012.03.043Search in Google Scholar PubMed PubMed Central

[46] Imataka, H., Gradi, A. and Sonenberg, N. A newly identified N-terminal amino acid sequence of human eIF4G binds poly(A)-binding protein and functions in poly(A)-dependent translation. EMBO J. 17 (1998) 7480–7489. http://dx.doi.org/10.1093/emboj/17.24.748010.1093/emboj/17.24.7480Search in Google Scholar PubMed PubMed Central

[47] Chow, L.M. and Baker, S.J. PTEN function in normal and neoplastic growth. Cancer Lett. 241 (2006) 184–196. http://dx.doi.org/10.1016/j.canlet.2005.11.04210.1016/j.canlet.2005.11.042Search in Google Scholar PubMed

[48] Graat, H.C., Carette, J.E., Schagen, F.H., Vassilev, L.T., Gerritsen, W.R., Kaspers, G.J., Wuisman, P.I. and van Beusechem, V.W. Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol. Cancer Ther. 6 (2007) 1552–1561. http://dx.doi.org/10.1158/1535-7163.MCT-06-063110.1158/1535-7163.MCT-06-0631Search in Google Scholar PubMed

[49] Wang, W. and El-Deiry, W.S. Restoration of p53 to limit tumor growth. Curr. Opin. Oncol. 20 (2008) 90–96. http://dx.doi.org/10.1097/CCO.0b013e3282f31d6f10.1097/CCO.0b013e3282f31d6fSearch in Google Scholar PubMed

[50] Shepard, H.M., Jin, P., Slamon, D.J., Pirot, Z. and Maneval, D.C. Herceptin. Handb. Exp. Pharmacol. 181 (2008) 183–219. http://dx.doi.org/10.1007/978-3-540-73259-4_910.1007/978-3-540-73259-4_9Search in Google Scholar PubMed

[51] Rivera, F., Vega-Villegas, M.E., Lopez-Brea, M.F. and Marquez, R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol. 47 (2008) 9–19. http://dx.doi.org/10.1080/0284186070170472410.1080/02841860701704724Search in Google Scholar PubMed

[52] Chresta, C.M., Davies, B.R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S.E., Vincent, J.P., Ellston, R., Jones, D., Sini, P., James, D., Howard, Z., Dudley, P., Hughes, G., Smith, L., Maguire, S., Hummersone, M., Malagu, K., Menear, K., Jenkins, R., Jacobsen, M., Smith, G.C., Guichard, S. and Pass, M. AZD8055 is a potent, selective, and orally bioavailable ATPcompetitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70 (2010) 288–298. http://dx.doi.org/10.1158/0008-5472.CAN-09-175110.1158/0008-5472.CAN-09-1751Search in Google Scholar PubMed

[53] Sangai, T., Akcakanat, A., Chen, H., Tarco, E., Wu, Y., Do, K.A., Miller, T.W., Arteaga, C.L., Mills, G.B., Gonzalez-Angulo, A.M. and Meric-Bernstam, F. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin. Cancer Res. 18 (2012) 5816–5828. http://dx.doi.org/10.1158/1078-0432.CCR-12-114110.1158/1078-0432.CCR-12-1141Search in Google Scholar PubMed PubMed Central

[54] Vousden, K.H. and Lane, D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 275–283. http://dx.doi.org/10.1038/nrm214710.1038/nrm2147Search in Google Scholar PubMed